Stockreport

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD Inc.  (NSPR) 
NASDAQ:AMEX Investor Relations: inspiremd.com/en/investors/investor-relations
PDF TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) fo [Read more]